Cannabis is all the craze right now, especially CBD.
Most products are perfectly fine and useful to ingest, however, when something is this hot, there are bound to be some sketchy people getting involved.
This has proven to be the case of OTC listed company Pot Network Holdings (POTN.OTC). A popular line of cannabis-derived CBD products from a POTN subsidiary was found to be tainted with a dangerous synthetic cannabinoid known as 5F-ADB and DXM.
The manufacturer of the allegedly tainted products, Diamond CBD, markets a line of hemp-based oils and e-liquids, the best known of which is Chong’s Choice, endorsed by the 1970s comedian and celebrity stoner Tommy Chong of Cheech and Chong.
Diamond CBD’s chief executive officer said he was surprised to learn about tainted e-liquids. “Our products are all subject to third-party testing,” said Kevin Hagen, who was in Las Vegas attending the MJBiz Con, the world’s largest marijuana and hemp business conference. “I suppose any type of product could be tampered with or modified by someone with a syringe.”
However, something doesn’t quite add up.
The researchers at Virginia Commonwealth, in Richmond, recently tested a suite of nine Diamond CBD products. In two separately purchased samples, they found the synthetic cannabinoid 5F-ADB in Liquid Gold Strawberry e-liquid. The toxic compound also was discovered in Liquid Gold Jungle Juice e-liquid and Diamond CBD Vape Additive.
In another sample of the vape additive, they found Dextromethorphan (DXM), a chemical normally used as a cough suppressant.
“The finding of both 5F-ADB and DXM were both unexpected,” said researcher Justin L. Poklis, who was the primary author of the article published in the journal Forensic Science International.
Chemical Breakdown Of Tested Products
According to Pubmed, N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine methyl ester (5F-ADB) is one of the most potent synthetic cannabinoids and elicits severe psychotic symptoms in humans.
To investigate the neuronal mechanisms underlying its toxicity, we examined the effects of 5F-ADB on midbrain dopaminergic and serotonergic systems, which modulate various basic brain functions such as those in reward-related behavior. 5F-ADB-induced changes in spontaneous firing activity of dopaminergic and serotonergic neurons were recorded by ex vivo electrophysiological techniques. In dopaminergic neurons, 5F-ADB (1 μM) significantly increased the spontaneous firing rate, while 5F-ADB failed to activate dopaminergic neurons in the presence of the CB1 antagonist AM251 (1 μM).
However, the same concentration of 5F-ADB did not affect serotonergic-neuron activity. These results suggest that 5F-ADB activates local CB1 receptors and potentiates midbrain dopaminergic systems with no direct effects on midbrain serotonergic systems.